Spasticity in multiple sclerosis: Results of a patient survey

International Journal of Neuroscience

Volumn 123, Issue 6, 2013, Pages 400-408

  Oreja Guevara, C ^a   Gonzalez Segura D ^b   Vila, C ^b  

^a HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^b Almirall SA ^*  (Spain)

Author keywords

Disability; Healthcare resources; Healthcare survey; Multiple sclerosis; Spain; Spasticity

Indexed keywords

ADULT; ALTERNATIVE MEDICINE; ARTICLE; CLINICAL FEATURE; CROSS-SECTIONAL STUDY; DEMOGRAPHY; DISEASE DURATION; DISEASE EXACERBATION; DISEASE SEVERITY; FEMALE; HEALTH CARE SURVEY; HEALTH CARE UTILIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL PRACTICE; MULTIPLE SCLEROSIS; PHYSICAL DISABILITY; PREVALENCE; QUESTIONNAIRE; REHABILITATION CARE; SOCIAL ASPECT; SPASTICITY; UNITED STATES; WALKING DIFFICULTY; WEB BROWSER;

ADULT; COST OF ILLNESS; CROSS-SECTIONAL STUDIES; FEMALE; HEALTH SURVEYS; HUMANS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; MUSCLE SPASTICITY; PREVALENCE; SEVERITY OF ILLNESS INDEX; SPAIN;

EID: 84878024159     PISSN: 00207454     EISSN: 15635279     Source Type: Journal    
DOI: 10.3109/00207454.2012.762364     Document Type: Article

References (20)

1. Rizzo MA, Hadjimichael OC, Preiningerova J, Vollmer TL.Prevalence and treatment of spasticity reported by multiple sclerosispatients. Mult Scler 2004;10(5):589-95.
2. Stevenson VL. Rehabilitation in practice: spasticity management.Clin Rehabil 2010;24(4):293-304.
3. Sosnoff JJ, Gappmaier E, Frame A,Motl RW. Influence of spasticityon mobility and balance in persons with multiple sclerosis.J Neurol Phys Ther 2011;35(3):129-32.
4. Barnes MP, Kent RM, Semlyen JK, McMullen KM. Spasticityin multiple sclerosis. Neurorehabil Neural Repair2003;17(1):66-70.
5. de Sa JC, Airas L, Bartholome E, et al. Symptomatic therapy inmultiple sclerosis: a review for amultimodal approach in clinicalpractice. Ther Adv Neurol Disord 2011;4(3):139-68.
6. Oreja-Guevara C. Tratamiento de la espasticidad en la esclerosisḿ ultiple: nuevas perspectivas con el uso de cannabinoides[Treatment of spasticity in multiple sclerosis: new perspectivesregarding the use of cannabinoids]. Rev Neurol2012;55(7):421-30.
7. Zwibel HL. Contribution of impaired mobility and generalsymptoms to the burden of multiple sclerosis. Adv Ther2009;26(12):1043-57.
8. Hemmett L, Holmes J, BarnesM, Russell N. What drives qualityof life in multiple sclerosis? QJM 2004;97(10):671-6.
9. BuhseM. Assessment of caregiver burden in families of personswith multiple sclerosis. J Neurosci Nurs 2008;40(1):25-31.
10. Vivancos-Matellano F, Pascual-Pascual SI, Nardi-VilardagaJ, et al; for Spanish Group on Spasticity. Guide to the comprehensive treatment of spasticity. [Article in Spanish]. RevNeurol 2007;45(6):365-75.
11. Arroyo R, Vila C, Clissold S. Retrospective observational studyof the management of multiple sclerosis patients with resistantspasticity in Spain: the '5E' study. Expert Rev PharmacoeconOutcomes Res 2011;11(2):205-13.
12. Ares B, Prieto JM, Lema M, et al. Prevalence of multiple sclerosisin Santiago de Compostela (Galicia, Spain). Mult Scler2007;13(2):262-4.
13. Confavreux C. The natural history of multiple sclerosis. In:Compston A, et al., eds. McAlpine's multiple sclerosis. 4th ed.Oxford: Churchill Livingstone/Elsevier; 2005: 199.
14. Orton SM, Herrera BM, Yee IM, et al; for Canadian CollaborativeStudy Group. Sex ratio of multiple sclerosis in Canada: alongitudinal study. Lancet Neurol 2006;5(11):932-6.
15. Pugliatti M, Rosati G, Carton H, et al. The epidemiology ofmultiple sclerosis in Europe. Eur J Neurol 2006;13(7):700-22.
16. Khan F, Amatya B, Turner-Stokes L. Symptomatic therapy andrehabilitation in primary progressive multiple sclerosis. NeurolRes Int 2011;2011:740505.
17. Antel J, Antel S, Caramanos Z, et al. Primary progressive multiplesclerosis: part of theMSdisease spectrumor separate diseaseentity? Acta Neuropathol 2012;123(5):627-38.
18. Otero S, Batlle J, Bonaventura I, et al; for Grupo de Trabajodel Registro de Esclerosis Ḿultiple de Catalũ na. Multiple sclerosisepidemiological situation update: pertinence and set-up ofa population based registry of new cases in Catalonia. [Articlein Spanish]. Rev Neurol 2010;50(10):623-33.
19. Modrego Pardo PJ, Latorre MA, Ĺopez A, Errea JM. Prevalenceof multiple sclerosis in the province of Teruel, Spain. J Neurol1997;244(3):182-5.
20. Oreja-Guevara C. Clinical efficacy and effectiveness of Sativex,a combined cannabinoid medicine, in multiple sclerosis-relatedspasticity. Expert Rev Neurother 2012;12(4 Suppl):3-8.